Name: Ceryvyn Therapeutics (CYV) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

CYV

Pharmaceuticals, Biotechnology & Life Sciences

Ceryvyn Therapeutics

Short interest: 0.23%; −0.05 pp 30d; as of 7 Oct 2026
Reported shorts: 3.2M
Shares on issue: 1.368B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Ceryvyn Therapeutics

Company profile →

Ceryvyn Therapeutics (ASX:CYV) has 0.23% of its shares on issue reported as short positions as of 7 Oct 2026, or about 3,196,278 shares. Over the past 30 days that figure has fallen 0.05 percentage points, and over 90 days it has risen 0.23 percentage points. Its highest recorded short interest was 0.97% in September 2026. CYV is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads CYV today

Zanger BreakoutWatchScore 20rank 1231 of 1951
CAN SLIMWatchScore 20rank 660 of 1533
Minervini Trend TemplateWatchScore 12rank 1277 of 1752
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 15rank 979 of 1691

Prices to 12 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

CYV fundamentals

In the year to 30 Jun 2026, Ceryvyn Therapeutics (ASX:CYV) recorded revenue of A$1.0K and net profit after tax of A$330.4M. A year earlier it recorded revenue of A$228.0K and a net loss after tax of A$251.1M. Net margin 33,044,500.0% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 29 Sep 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →